Business Insider28 天
Promising Market Potential and Strategic Growth Drive Buy Rating for Tarsus Pharmaceuticals
Analyst Cory Jubinville, PhD of LifeSci Capital maintained a Buy rating on Tarsus Pharmaceuticals (TARS – Research Report), retaining the price target of $67.00. Cory Jubinville, PhD has given ...